Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nido Biosciences has announced positive results from a ...
BOSTON--(BUSINESS WIRE)--Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, today announced a new publication in Neurology ®, ...
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical ...
Spinal and bulbar muscular atrophy (SBMA) is a rare X-linked neuromuscular disorder that results from an abnormal expansion of gene sequences in the androgen receptor gene. SBMA has an adult onset and ...
MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies ...
MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results